Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. PEG Ratio is defined as the PE Ratio divided by the growth ratio. To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. If a company loses money, the PE Ratio becomes meaningless. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive.
As a shareholder, you want the company to earn back the price you pay as soon as possible. If a company's earnings decline it takes more years. 13F filings are submitted quarterly to the SEC by hedge funds and other investment managers. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. View 13F filing holders of Montes Archimedes Acquisition Corp.
About Company Business: Montes Archimedes Acquisition Corp is a shell company with a Special Purpose Acquisition Company with a focus on the health care industry. In real business, earnings never stay constant. Company Website: MONTES ARCHIMEDES ACQUISITION CORP. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. This page offers an in-depth profile of Montes Archimedes Acquisition Corp, including a general overview of the company's business and key management. Montes Archimedes Acquisition (NAS:MAAC) PE Ratio Explanation Payments to Suppliers for Goods and Services.Other Cash Receipts from Operating Activities.Other Cash Payments from Operating Activities.Cash Received from Insurance Activities.Cash Receipts from Securities Related Activities.Cash Receipts from Operating Activities.Cash Receipts from Fees and Commissions.Cash Receipts from Deposits by Banks and Customers.Cash Payments for Deposits by Banks and Customers.Cash from Discontinued Operating Activities.Cash From Discontinued Investing Activities.Short-Term Debt & Capital Lease Obligation.Other Liabilities for Insurance Companies.
The transaction is expected to close in the third quarter of 2021. "We look forward to continuing to deliver important medicines to patients through our development engine and our rapidly growing drug discovery capabilities spanning multiple therapeutic areas and modalities." "I look forward to the next chapter of Roivant's growth by beginning our life as a public company with an exceptionally strong and diverse base of long-term investors," said Roivant CEO Matthew Gline. The new company will have a net cash position of $2.3 billion, which will be used to expand Roivant's product pipeline. The overall deal includes the $411 million held in the MAAC trust account and $200 million in PIPE financing from various healthcare investors. Through the deal, MAAC will be funding a company with a proven track record of success, having put over 40 medicines into development across a wide range of disease areas since its founding in 2014. What does this mean for Montes Archimedes Corp? Shares of MAAC increased 1.42% to $10 as of Monday at 11:43am. The new company will be listed on Nasdaq under the new ticker symbol "ROIV," with outstanding shares and warrants of MAAC to be exchanged for newly issued shares and warrants of Roivant Sciences at the close of the transaction. Montes Archimedes Acquisition ( MAAC) stock jumped today after the SPAC announced it had reached a merger agreement with Roivant Sciences, a biopharmaceutical and healthcare technology company.
0 kommentar(er)
